Skip to main content

Bardet-Biedl Syndrome

0
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
1100%
+ 3 programs with unclassified modality

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Rhythm Pharmaceuticals
2 programs
SetmelanotidePHASE_3Peptide1 trial
Setmelanotide 2 mgPHASE_31 trial
Active Trials
NCT04966741Completed12Est. Nov 2024
NCT05194124Completed19Est. Oct 2023
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Genetics and Clinical Characteristics of Bardet-Biedl SyndromeN/A1 trial
Active Trials
NCT00078091Terminated194Est. Feb 2016
Genome & Company
Genome & CompanyKorea - Suwon
1 program
Genetics and Clinical Characteristics of Bardet-Biedl SyndromeN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Rhythm PharmaceuticalsSetmelanotide
Rhythm PharmaceuticalsSetmelanotide 2 mg
Human BioSciencesGenetics and Clinical Characteristics of Bardet-Biedl Syndrome

Clinical Trials (3)

Total enrollment: 225 patients across 3 trials

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity

Start: Mar 2022Est. completion: Nov 202412 patients
Phase 3Completed

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

Start: Dec 2021Est. completion: Oct 202319 patients
Phase 3Completed
NCT00078091Human BioSciencesGenetics and Clinical Characteristics of Bardet-Biedl Syndrome

Genetics and Clinical Characteristics of Bardet-Biedl Syndrome

Start: Feb 2004Est. completion: Feb 2016194 patients
N/ATerminated

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.